## FREUND CORPORATION (6312)

| Consolidated FY (Million Yen) |  | Sales | Operating Profit | Recurring Profit | Profit Attributable to Owners of Parent | $\begin{aligned} & \text { EPS } \\ & \text { (Yen) } \end{aligned}$ | DPS <br> (Yen) | $\begin{aligned} & \text { BPS } \\ & \text { (Yen) } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| FY02/2017 |  | 21,164 | 2,041 | 2,097 | 1,064 | 61.7 | 20.0 | 706.6 |
| FY02/2018 |  | 19,801 | 1,971 | 1,994 | 1,477 | 85.7 | 20.0 | 767.9 |
| FY02/2019CoE |  | 20,000 | 1,900 | 1,900 | 1,350 | 78.3 | 20.0 |  |
| FY02/2018 | YoY | (6.4\%) | (3.4\%) | (4.9\%) | 38.8\% | - | - |  |
| FY02/2019CoE | YoY | 1.0\% | (3.6\%) | (4.7\%) | (8.6\%) | - | - |  |
| Consolidated Half Year (Million Yen) |  | Sales | Operating Profit | Recurring Profit | Profit Attributable to Owners of Parent | $\begin{aligned} & \text { EPS } \\ & \text { (Yen) } \end{aligned}$ | $\begin{aligned} & \text { DPS } \\ & \text { (Yen) } \end{aligned}$ | $\begin{aligned} & \text { BPS } \\ & \text { (Yen) } \end{aligned}$ |
| Q1 to Q2 FY02/2019 |  | 9,117 | 592 | 684 | 466 | - | - | - |
| Q3 to Q4 FY02/2019CoE |  | 10,882 | 1,307 | 1,215 | 883 | - | - | - |
| Q1 to Q2 FY02/2019 | YoY | (6.9\%) | (44.8\%) | (37.3\%) | (36.5\%) | - | - | - |
| Q3 to Q4 FY02/2019CoE | YoY | 8.7\% | 45.8\% | 34.7\% | 18.9\% | - | - | - |

### 1.0 Results Update (5 October 2018)

## Recovery of Order Intake

On 5 October 2018, FREUND CORPORATION, developing, manufacturing and selling equipment of pharmaceutical and industrial domains as the key earnings pillar, released its Q1 to Q2 FY02/2019 results. It has been revealed that order intake on the Equipment side sees a recovery due to large-scale project, while sales and earnings are buoyant on the Chemicals side. In Q1 to Q2, order intake on the Equipment side came in at $¥ 6,518 \mathrm{~m}$ (up $8.9 \% \mathrm{YoY}$ ), while $¥ 2,553 \mathrm{~m}$ in Q1 and $¥ 3,964 \mathrm{~m}$ in Q2, suggesting increases by no less than $55.2 \%$ on a quarter on quarter basis. As far as we could gather, the Company saw order intake on large-scale project overseas in regards to the mainstay pharmaceutical domain, which was the key driver. Increasing sales and earnings on the Chemicals side are basically in line with those of pharmaceutical excipients in J apan and overseas. In J apan, sales associated with generic drugs were favorable, while exports to India overseas. Meanwhile, given ongoing firm demand, the Company has decided to beef up capacity for pharmaceutical excipients as soon as possible.

We are to attend the Company's results meeting on 18 October in order to gather information more in depth as well as interviewing with management afterwards so that we should be able to update FREUND CORPORATION (6312) Still Slowing (2 August 2018) and to release anew.

### 2.0 Company Profile

Developing, Manufacturing and Selling Equipment for Pharmaceutical and Industrial Domains

| Company Name | FREUND CORPORATION <br> Company Website <br> IR Information <br> Share Price (J apanese) |
| :---: | :---: |
| Established | 22 April 1964 |
| Listing | 24 J uly 1996: Tokyo Stock Exchange J ASDAQ Standard (ticker: 6312) |
| Capital | $¥ 1,035 \mathrm{~m}$ (as of the end of August 2018) |
| No. of Shares | 18,400,000 shares, including 1,655,478 treasury shares (as of the end of Aug. 2018) |
| Main Features | - Leading the domestic market of J apan for granulation/coating equipment with market share of $60 \%$ to $70 \%$ <br> - One of the three largest on a global basis <br> - Focus on new fields, i.e., tablet-printing equipment (TABREX), rechargeable-battery-related manufacturing equipment, etc. |
| Business Segments | I. Equipment <br> II. Chemicals |
| Top M anagement | President \& CEO: I wao F usejima |
| Shareholders | KK Fusejima Yokosha 8.96\%, Yasutoyo Fusejima 7.18\%, MUFG Bank, Ltd. 4.54\% (as of the end of August 2018) |
| Headquarters | FREUND Bldg., 6-25-13 Nishishinjuku, Shinjuku-ku, Tokyo, J APAN |
| No. of Employees | Consolidated: 415, Parent: 241 (as of the end of August 2018) |

Source: Company Data

### 3.0 Recent Trading and Prospects

## Q1 to Q2 FY02/2019 Results

In Q1 to Q2 FY02/2019, sales came in at $¥ 9,117 \mathrm{~m}$ (down $6.9 \%$ YoY), operating profit $¥ 592 \mathrm{~m}$ (down $44.8 \%$ ), recurring profit $¥ 684$ m (down $37.3 \%$ ) and profit attributable to owners of parent $¥ 466 \mathrm{~m}$ (down $36.5 \%$ ), while operating profit margin $6.5 \%$ (down $4.5 \%$ points).


Source: Company Data, WRJ Calculation

By business segment, Equipment saw sales of $¥ 6,145$ m (down $14.3 \%$ ), segment profit of $¥ 291 \mathrm{~m}$ (down $66.5 \%$ ) and segment profit margin of $4.7 \%$ (down $7.4 \%$ points), while Chemicals sales of $¥ 2,971 \mathrm{~m}$ (up $13.5 \%$ ), segment profit of $¥ 556$ m (up $32.1 \%$ ) and segment profit margin of $18.7 \%$ (up $2.6 \%$ points). Meanwhile, the Company saw total segment profit (before elimination) of $¥ 847 \mathrm{~m}$ as a whole for the Company, suggesting that Equipment accounted for $34.4 \%$ of total and Chemicals $65.6 \%$. Over the past 5 years, Equipment used to account for some $70 \%$ and thus the Company saw almost a reversal of the said ratio between the two business segments as far as Q1 to Q2 results were concerned. This was due mainly to major adjustments of earnings on the Equipment side. Sales in J apan came in at $¥ 4,352 \mathrm{~m}$ (down $4.5 \%$ ) and sales overseas $¥ 1,793 \mathrm{~m}$ (down $31.4 \%$ ), having resulted in falling sales as a whole for the Equipment side, while gross profit margin was under pressure as far as we could see.

More importantly, however, order intake or leading indicator for sales is now recovering and order backlog picking up. In Q1 to Q2, order intake on the Equipment side came in at $¥ 6,518 \mathrm{~m}$ (up $8.9 \%$ YoY), while $\neq 2,553 \mathrm{~m}$ in Q1 and $¥ 3,964 \mathrm{~m}$ in Q2, suggesting increases by no less than $55.2 \%$ on a quarter on quarter basis. As far as we could gather, the Company saw order intake on large-scale project overseas in regards to the mainstay pharmaceutical domain, which was the key driver.


Equipment: Order Intake by Region


Source: Company Data, WRJ Calculation

On the Equipment side, sales and order intake comprise those of pharmaceutical and industrial domains. The mainstay equipment of pharmaceutical domain includes existing granulation/coating equipment as well as tablet-printing equipment (TABREX) belonging to new field. The Company's U.S. subsidiary FREUND-VECTOR CORPORATION in charge of the operations overseas mainly in North America saw order intake on large-scale project of granulation/coating equipment, while tablet-printing equipment (TABREX) introduced in J apan suffered from shortfall of order intake when compared with initial expectations, according to the Company. As a result, it appears that existing granulation/coating equipment has remained accounting for the bulk of sales and order intake, driving order intake on the Equipment side as a whole with its strengths.


Source: Company Data, WRJ Calculation

FY02/2019 Company Forecasts
FY02/2019 initial Company forecasts have remained unchanged, going for prospective sales of $¥ 20,000 \mathrm{~m}$ (up $1.0 \%$ YoY), operating profit of $¥ 1,900 \mathrm{~m}$ (down $3.6 \%$ ), recurring profit of $¥ 1,900 \mathrm{~m}$ (down $4.7 \%$ ) and profit attributable to owners of parent of $¥ 1,350 \mathrm{~m}$ (down $8.6 \%$ ), while operating profit margin of $9.5 \%$ (down $0.5 \%$ points). At the same time, Company forecasts have remained unchanged for prospective dividend, going for $¥ 20.0$ per share, implying payout ratio of $25.5 \%$.

### 4.0 Financial Statements

Income Statement (Cumulative, Quarterly)

| Income Statement (Million Yen) | Cons.Act Q1 02/2018 | $\begin{aligned} & \text { Cons.Act } \\ & \text { Q1 to Q2 } \\ & \text { 02/2018 } \end{aligned}$ | $\begin{aligned} & \text { Cons.Act } \\ & \text { Q1 to Q3 } \\ & \text { 02/2018 } \end{aligned}$ | $\begin{aligned} & \text { Cons.Act } \\ & \text { Q1 to Q4 } \\ & 02 / 2018 \end{aligned}$ | $\begin{array}{r} \text { Cons. Act } \\ \text { Q1 } \\ 02 / 2019 \end{array}$ | Cons.Act Q1 to Q2 02/2019 | Cons.Act Q1 to Q3 02/2019 | $\begin{array}{r} \text { Cons.Act } \\ \text { Q1 to Q4 } \\ 02 / 2019 \end{array}$ | Net Chg. |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Sales | 4,472 | 9,789 | 13,745 | 19,801 | 4,849 | 9,117 | - | - | (671) |
| Cost of Sales | 2,915 | 6,317 | 8,993 | 12,985 | 3,245 | 6,100 | - | - | (216) |
| Gross Profit | 1,556 | 3,471 | 4,752 | 6,816 | 1,604 | 3,016 | - | - | (455) |
| SG\&A | 1,169 | 2,397 | 3,599 | 4,845 | 1,204 | 2,423 | - | - | +26 |
| Operating Profit | 387 | 1,074 | 1,152 | 1,971 | 399 | 592 | - | - | (481) |
| Non Operating Balance | 10 | 17 | 21 | 22 | 79 | 91 | - | - | +74 |
| Recurring Profit | 397 | 1,091 | 1,174 | 1,994 | 478 | 684 | - | - | (407) |
| Extraordinary Balance | 0 | (1) | 59 | 99 | 21 | 21 | - | - | +23 |
| Profit before Income Taxes | 397 | 1,089 | 1,234 | 2,093 | 500 | 705 | - | - | (383) |
| Total Income Taxes | 123 | 355 | 384 | 615 | 153 | 239 | - | - | (115) |
| NP Belonging to Non-Controlling SHs | - | - | - | - | - | - | - | - |  |
| Profit Attributable to Owners of Parent | 274 | 734 | 849 | 1,477 | 347 | 466 | - | - | (268) |
| Sales YoY | +14.3\% | +11.7\% | (6.9\%) | (6.4\%) | +8.4\% | (6.9\%) | - | - | - |
| Operating Profit YoY | +31.3\% | +56.4\% | (20.0\%) | (3.4\%) | +3.0\% | (44.8\%) | - | - | - |
| Recurring Profit YoY | +26.7\% | +54.0\% | (21.0\%) | (4.9\%) | +20.3\% | (37.3\%) | - | - |  |
| Profit Attributable to Owners of Parent YoY | +464.9\% | +139.7\% | +4.1\% | +38.8\% | +26.6\% | (36.5\%) | - | - | - |
| Gross Profit Margin | 34.8\% | 35.5\% | 34.6\% | 34.4\% | 33.1\% | 33.1\% | - | - | (2.4\%) |
| SG\&A / Sales | 26.1\% | 24.5\% | 26.2\% | 24.5\% | 24.8\% | 26.6\% | - | - | +2.1\% |
| Operating Profit Margin | 8.7\% | 11.0\% | 8.4\% | 10.0\% | 8.2\% | 6.5\% | - | - | (4.5\%) |
| Recurring Profit Margin | 8.9\% | 11.2\% | 8.5\% | 10.1\% | 9.9\% | 7.5\% | - | - | (3.6\%) |
| Profit Attributable to Owners of Parent Margin | 6.1\% | 7.5\% | 6.2\% | 7.5\% | 7.2\% | 5.1\% | - | - | (2.4\%) |
| Total Income Taxes / Profit before Income Taxes | 31.0\% | 32.6\% | 31.2\% | 29.4\% | 30.6\% | 33.9\% | - | - | +1.4\% |
| Income Statement | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act |  |
|  | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | YoY |
| (Million Yen) | 02/2018 | 02/2018 | 02/2018 | 02/2018 | 02/2019 | 02/2019 | 02/2019 | 02/2019 | Net Chg. |
| Sales | 4,472 | 5,316 | 3,956 | 6,055 | 4,849 | 4,267 | - | - | $(1,049)$ |
| Cost of Sales | 2,915 | 3,401 | 2,675 | 3,991 | 3,245 | 2,855 | - | - | (546) |
| Gross Profit | 1,556 | 1,915 | 1,280 | 2,063 | 1,604 | 1,412 | - | - | (503) |
| SG\&A | 1,169 | 1,227 | 1,202 | 1,245 | 1,204 | 1,218 | - | - | (9) |
| Operating Profit | 387 | 687 | 78 | 818 | 399 | 193 | - | - | (493) |
| Non Operating Balance | 10 | 6 | 4 | 1 | 79 | 11 | - | - | +5 |
| Recurring Profit | 397 | 693 | 82 | 819 | 478 | 205 | - | - | (488) |
| Extraordinary Balance | 0 | (1) | 61 | 39 | 21 | 0 | - | - | +1 |
| Profit before Income Taxes | 397 | 691 | 144 | 858 | 500 | 205 | - | - | (486) |
| Total Income Taxes | 123 | 231 | 29 | 230 | 153 | 86 | - | - | (145) |
| NP Belonging to Non-Controlling SHs | - | - | - | - | - | - | - | - | - |
| Profit Attributable to Owners of Parent | 274 | 460 | 114 | 628 | 347 | 118 | - | - | (341) |
| Sales YoY | +14.3\% | +9.6\% | (34.1\%) | (5.3\%) | +8.4\% | (19.7\%) | - | - | - |
| Operating Profit YoY | +31.3\% | +75.2\% | (89.6\%) | +36.3\% | +3.0\% | (71.8\%) | - | - | - |
| Recurring Profit YoY | +26.7\% | +75.7\% | (89.4\%) | +34.2\% | +20.3\% | (70.4\%) | - | - | - |
| Profit Attributable to Owners of Parent YoY | +464.9\% | +78.5\% | (77.4\%) | +152.7\% | +26.6\% | (74.1\%) | - | - | - |
| Gross Profit Margin | 34.8\% | 36.0\% | 32.4\% | 34.1\% | 33.1\% | 33.1\% | - | - | (2.9\%) |
| SG\&A / Sales | 26.1\% | 23.1\% | 30.4\% | 20.6\% | 24.8\% | 28.5\% | - | - | +5.5\% |
| Operating Profit Margin | 8.7\% | 12.9\% | 2.0\% | 13.5\% | 8.2\% | 4.5\% | - | - | (8.4\%) |
| Recurring Profit Margin | 8.9\% | 13.1\% | 2.1\% | 13.5\% | 9.9\% | 4.8\% | - | - | (8.2\%) |
| Profit Attributable to Owners of Parent Margin | 6.1\% | 8.7\% | 2.9\% | 10.4\% | 7.2\% | 2.8\% | - | - | (5.9\%) |
| Total Income Taxes / Profit before Income Taxes | 31.0\% | 33.5\% | 20.6\% | 26.8\% | 30.6\% | 42.1\% | - | - | +8.6\% |

Segmented Information (Cumulative, Quarterly)

| Segmented Information (Million Yen) | Cons.Act Q1 02/2018 | Cons.Act Q1 to Q2 02/2018 | Cons.Act Q1 to Q3 02/2018 | Cons.Act Q1 to Q4 02/2018 | Cons.Act <br> 02/2019 | Cons.Act Q1 to Q2 02/2019 | Cons.Act Q1 to Q3 02/2019 | Cons.Act <br> Q1 to Q4 02/2019 | Net Chg. |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Equipment | 3,198 | 7,171 | 9,747 | 14,403 | 3,433 | 6,145 | - | - | $(1,025)$ |
| Chemicals | 1,274 | 2,617 | 3,998 | 5,398 | 1,416 | 2,971 | - |  | +353 |
| Sales | 4,472 | 9,789 | 13,745 | 19,801 | 4,849 | 9,117 | - | - | (671) |
| Machinery | +32.5\% | +25.9\% | (2.6\%) | (3.4\%) | +7.4\% | (14.3\%) |  | - | - |
| Chemicals | (15.0\%) | (14.6\%) | (16.1\%) | (13.6\%) | +11.1\% | +13.5\% | - | - | - |
| Sales (YoY) | +14.3\% | +11.7\% | (6.9\%) | (6.4\%) | +8.4\% | (6.9\%) | - | - | - |
| Equipment | 71.5\% | 73.3\% | 70.9\% | 72.7\% | 70.8\% | 67.4\% | - | - | - |
| Chemicals | 28.5\% | 26.7\% | 29.1\% | 27.3\% | 29.2\% | 32.6\% | - | - | - |
| Sales (Composition Ratio) | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | - | - | - |
| Equipment | 326 | 868 | 910 | 1,631 | 278 | 291 | - |  | (577) |
| Chemicals | 196 | 420 | 593 | 801 | 259 | 556 | - | - | +135 |
| Segment Profit | 522 | 1,289 | 1,504 | 2,432 | 537 | 847 | - | - | (442) |
| Elimination | (135) | (215) | (351) | (461) | (138) | (254) | - | - | (39) |
| Operating Profit | 387 | 1,074 | 1,152 | 1,971 | 399 | 592 | - | - | (481) |
| Equipment | +48.1\% | +53.1\% | (21.1\%) | (6.8\%) | (14.8\%) | (66.5\%) |  | - | - |
| Chemicals | +10.1\% | +17.9\% | (1.4\%) | +7.1\% | +32.5\% | +32.1\% | - | - | - |
| Segment Profit (YoY) | +31.1\% | +39.5\% | (14.3\%) | (2.6\%) | +2.9\% | (34.3\%) | - | - | - |
| Equipment | 62.5\% | 67.4\% | 60.5\% | 67.1\% | 51.7\% | 34.4\% |  |  |  |
| Chemicals | 37.5\% | 32.6\% | 39.5\% | 32.9\% | 48.3\% | 65.6\% | - | - | - |
| Segment Profit (Composition Ratio) | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | - | - | - |
| Equipment | 10.2\% | 12.1\% | 9.3\% | 11.3\% | 8.1\% | 4.7\% | - |  | (7.4\%) |
| Chemicals | 15.4\% | 16.1\% | 14.9\% | 14.8\% | 18.3\% | 18.7\% | - | - | +2.6\% |
| Elimination | (3.0\%) | (2.2\%) | (2.6\%) | (2.3\%) | (2.9\%) | (2.8\%) |  | - | (0.6\%) |
| Operating Profit Margin | 8.7\% | 11.0\% | 8.4\% | 10.0\% | 8.2\% | 6.5\% | - | - | (4.5\%) |
| Segmented Information | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act |  |
|  | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | YoY |
| (Million Yen) | 02/2018 | 02/2018 | 02/2018 | 02/2018 | 02/2019 | 02/2019 | 02/2019 | 02/2019 | Net Chg. |
| Equipment | 3,198 | 3,973 | 2,575 | 4,655 | 3,433 | 2,712 | - | - | $(1,261)$ |
| Chemicals | 1,274 | 1,343 | 1,381 | 1,399 | 1,416 | 1,555 | - | - | +211 |
| Sales | 4,472 | 5,316 | 3,956 | 6,055 | 4,849 | 4,267 | - | - | $(1,049)$ |
| Machinery | +32.5\% | +21.0\% | (40.2\%) | (5.2\%) | +7.4\% | (31.7\%) |  |  | - |
| Chemicals | (15.0\%) | (14.2\%) | (18.7\%) | (5.8\%) | +11.1\% | + 15.8\% | - | - | - |
| Sales (YoY) | +14.3\% | +9.6\% | (34.1\%) | (5.3\%) | +8.4\% | (19.7\%) | - | - | - |
| Equipment | 71.5\% | 74.7\% | 65.1\% | 76.9\% | 70.8\% | 63.6\% |  | - | - |
| Chemicals | 28.5\% | 25.3\% | 34.9\% | 23.1\% | 29.2\% | 36.4\% | - | - | - |
| Sales (Composition Ratio) | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | - | - | - |
| Equipment | 326 | 542 | 41 | 720 | 278 | 13 | - | - | (529) |
| Chemicals | 196 | 224 | 172 | 207 | 259 | 296 | - | - | +71 |
| Segment Profit | 522 | 767 | 214 | 927 | 537 | 309 | - | - | (457) |
| Elimination | (135) | (80) | (136) | (109) | (138) | (116) | - | - | (36) |
| Operating Profit | 387 | 687 | 78 | 818 | 399 | 193 | - | - | (493) |
| Equipment | +48.1\% | +56.2\% | (92.9\%) | +20.9\% | (14.8\%) | (97.5\%) | - | - | - |
| Chemicals | +10.1\% | +25.7\% | (29.4\%) | +41.7\% | +32.5\% | +31.9\% | - | - | - |
| Segment Profit (YoY) | +31.1\% | +45.8\% | (74.2\%) | +25.0\% | +2.9\% | (59.6\%) | - | - | - |
| Equipment | 62.5\% | 70.7\% | 19.5\% | 77.7\% | 51.7\% | 4.3\% | - | - | - |
| Chemicals | 37.5\% | 29.3\% | 80.5\% | 22.3\% | 48.3\% | 95.7\% | - | - | - |
| Segment Profit (Composition Ratio) | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | - | - | - |
| Equipment | 10.2\% | 13.7\% | 1.6\% | 15.5\% | 8.1\% | 0.5\% | - | - | (13.2\%) |
| Chemicals | 15.4\% | 16.7\% | 12.5\% | 14.8\% | 18.3\% | 19.1\% | - | - | +2.3\% |
| Elimination | (3.0\%) | (1.5\%) | (3.5\%) | (1.8\%) | (2.9\%) | (2.7\%) | - | - | (1.2\%) |
| Operating Profit Margin | 8.7\% | 12.9\% | 2.0\% | 13.5\% | 8.2\% | 4.5\% | - | - | (8.4\%) |

Source: Company Data, WRJ Calculation

Sales by Region: Equipment (Cumulative, Quarterly)

| Sales by Region: Equipment (Million Yen) | $\begin{array}{r} \text { Cons.Act } \\ \text { Q1 } \\ \text { 02/2018 } \end{array}$ | $\begin{gathered} \text { Cons. Act } \\ \text { Q1 to Q2 } \\ 02 / 2018 \end{gathered}$ | $\begin{array}{r} \text { Cons.Act } \\ \text { Q1 to Q3 } \\ 02 / 2018 \end{array}$ | $\begin{gathered} \text { Cons.Act } \\ \text { Q1 to Q4 } \\ 02 / 2018 \end{gathered}$ | $\begin{array}{r} \text { Cons.Act } \\ \text { Q1 } \\ 02 / 2019 \end{array}$ | $\begin{array}{r} \text { Cons.Act } \\ \text { Q1 to Q2 } \\ 02 / 2019 \end{array}$ | $\begin{array}{r} \text { Cons.Act } \\ \text { Q1 to Q3 } \\ 02 / 2019 \end{array}$ | Cons.Act Q1 to Q4 02/2019 | $\begin{array}{r} \text { YoY } \\ \text { Net Chg. } \end{array}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Japan | 2,566 | 4,559 | 5,883 | 8,493 | 2,783 | 4,352 | - | - | (207) |
| North America \& Latin America | 331 | 1,119 | 1,795 | 2,979 | 289 | 1,007 | - | - | (112) |
| Europe \& Africa | 210 | 1,018 | 1,287 | 1,782 | 80 | 141 | - | - | (876) |
| Middle East, Asia \& Oceania | 88 | 473 | 781 | 1,147 | 279 | 643 | - | - | +169 |
| Overseas | 631 | 2,612 | 3,864 | 5,909 | 649 | 1,793 | - | - | (818) |
| Sales | 3,198 | 7,171 | 9,747 | 14,403 | 3,433 | 6,145 | - | - | $(1,025)$ |
| Japan | +41.1\% | +8.7\% | (16.4\%) | (10.2\%) | +8.5\% | (4.5\%) | - | - | - |
| North America \& Latin America | (24.2\%) | +1.4\% | (5.9\%) | (23.3\%) | (12.7\%) | (10.0\%) | - | - | - |
| Europe \& Africa | +127.0\% | +286.3\% | +203.4\% | +105.4\% | (62.0\%) | (86.1\%) | - | - | - |
| Middle East, Asia \& Oceania | +39.7\% | +251.8\% | +23.6\% | +63.3\% | +215.0\% | +35.8\% | - | - | - |
| Overseas | +6.3\% | +73.8\% | +30.4\% | +8.3\% | +2.9\% | (31.4\%) | - | - | - |
| Sales (YoY) | +32.5\% | +25.9\% | (2.6\%) | (3.4\%) | +7.4\% | (14.3\%) | - | - | - |
| Japan | 80.3\% | 63.6\% | 60.4\% | 59.0\% | 81.1\% | 70.8\% | - | - | - |
| North America \& Latin America | 10.4\% | 15.6\% | 18.4\% | 20.7\% | 8.4\% | 16.4\% | - | - | - |
| Europe \& Africa | 6.6\% | 14.2\% | 13.2\% | 12.4\% | 2.3\% | 2.3\% | - | - | - |
| Middle East, Asia \& Oceania | 2.8\% | 6.6\% | 8.0\% | 8.0\% | 8.2\% | 10.5\% | - | - | - |
| Overseas | 19.7\% | 36.4\% | 39.6\% | 41.0\% | 18.9\% | 29.2\% | - | - | - |
| Sales (Composition) | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | - | - | - |
| Sales by Region: Equipment | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act |  |
|  | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | YoY |
| (Million Yen) | 02/2018 | 02/2018 | 02/2018 | 02/2018 | 02/2019 | 02/2019 | 02/2019 | 02/2019 | Net Chg. |
| Japan | 2,566 | 1,992 | 1,323 | 2,610 | 2,783 | 1,568 | - | - | (424) |
| North America \& Latin America | 331 | 788 | 675 | 1,184 | 289 | 718 | - | - | (69) |
| Europe \& Africa | 210 | 807 | 269 | 494 | 80 | 61 | - | - | (746) |
| Middle East, Asia \& Oceania | 88 | 385 | 307 | 365 | 279 | 363 | - | - | (21) |
| Overseas | 631 | 1,980 | 1,252 | 2,045 | 649 | 1,143 | - | - | (837) |
| Sales | 3,198 | 3,973 | 2,575 | 4,655 | 3,433 | 2,712 | - | - | $(1,261)$ |
| Japan | +41.1\% | (16.1\%) | (53.5\%) | +7.9\% | +8.5\% | (21.3\%) | - | - | - |
| North America \& Latin America | (24.2\%) | +18.2\% | (15.8\%) | (40.1\%) | (12.7\%) | (8.8\%) | - | - | - |
| Europe \& Africa | +127.0\% | +373.0\% | +67.5\% | +11.6\% | (62.0\%) | (92.4\%) | - | - | - |
| Middle East, Asia \& Oceania | +39.7\% | +441.6\% | (38.2\%) | +419.0\% | +215.0\% | (5.5\%) | - | - | - |
| Overseas | +6.3\% | +118.0\% | (14.3\%) | (17.9\%) | +2.9\% | (42.3\%) | - | - | - |
| Sales (YoY) | +32.5\% | +21.0\% | (40.2\%) | (5.2\%) | +7.4\% | (31.7\%) | - | - | - |
| Japan | 80.3\% | 50.2\% | 51.4\% | 56.1\% | 81.1\% | 57.8\% | - | - | - |
| North America \& Latin America | 10.4\% | 19.8\% | 26.2\% | 25.4\% | 8.4\% | 26.5\% | - | - | - |
| Europe \& Africa | 6.6\% | 20.3\% | 10.5\% | 10.6\% | 2.3\% | 2.3\% | - | - | - |
| Middle East, Asia \& Oceania | 2.8\% | 9.7\% | 11.9\% | 7.9\% | 8.2\% | 13.4\% | - | - | - |
| Overseas | 19.7\% | 49.8\% | 48.6\% | 43.9\% | 18.9\% | 42.2\% | - | - | - |
| Sales (Composition) | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | 100.0\% | - | - | - |

Source: Company Data, WRJ Calculation

Balance Sheet (Quarterly)

| Balance Sheet | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act | Cons.Act |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | YoY |
| (Million Yen) | 02/2018 | 02/2018 | 02/2018 | 02/2018 | 02/2019 | 02/2019 | 02/2019 | 02/2019 | Net Chg. |
| Cash \& Deposit | 6,152 | 6,000 | 6,392 | 6,568 | 5,236 | 5,245 | - | - | (754) |
| Accounts Receivables | 4,352 | 5,028 | 4,341 | 4,451 | 4,576 | 4,377 | - | - | (650) |
| Inventory | 3,094 | 3,344 | 4,061 | 3,185 | 2,998 | 2,802 | - | - | (542) |
| Other | 720 | 639 | 718 | 579 | 545 | 566 | - | - | (72) |
| Current Assets | 14,320 | 15,012 | 15,514 | 14,784 | 13,356 | 12,991 | - | - | $(2,021)$ |
| Tangible Assets | 3,205 | 3,219 | 3,355 | 3,370 | 3,471 | 3,554 | - | - | +334 |
| Intangible Assets | 43 | 32 | 20 | 102 | 96 | 91 | - | - | +58 |
| Investments \& Other Assets | 869 | 857 | 864 | 868 | 860 | 847 | - | - | (9) |
| Fixed Assets | 4,118 | 4,109 | 4,240 | 4,341 | 4,428 | 4,493 | - | - | +383 |
| Total Assets | 18,439 | 19,122 | 19,755 | 19,125 | 17,784 | 17,484 | - | - | $(1,637)$ |
| Accounts Payables | 2,893 | 3,289 | 3,273 | 2,823 | 2,510 | 2,142 | - | - | $(1,147)$ |
| Short Term Debt | - | - | - | - | - | - | - | - | - |
| Other | 3,139 | 2,966 | 3,458 | 2,741 | 2,258 | 2,169 | - | - | (797) |
| Current Liabilities | 6,033 | 6,256 | 6,731 | 5,564 | 4,768 | 4,312 | - | - | $(1,944)$ |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Other | 325 | 333 | 336 | 318 | 323 | 319 | - | - | (13) |
| Fixed Liabilities | 325 | 333 | 336 | 318 | 323 | 319 | - | - | (13) |
| Total Liabilities | 6,358 | 6,589 | 7,067 | 5,883 | 5,092 | 4,632 | - | - | $(1,957)$ |
| Shareholders' Equity | 12,339 | 12,800 | 12,915 | 13,543 | 12,973 | 13,092 | - | - | +292 |
| Adjustments | (258) | (267) | (226) | (301) | (281) | (240) | - | - | +27 |
| Total Assets | 12,081 | 12,532 | 12,688 | 13,242 | 12,691 | 12,852 | - | - | +320 |
| Total Liabilities \& Net Assets | 18,439 | 19,122 | 19,755 | 19,125 | 17,784 | 17,484 | - | - | $(1,637)$ |
| Equity Capital | 12,081 | 12,532 | 12,688 | 13,242 | 12,691 | 12,852 | - | - | +320 |
| Interest Bearing Debt | - | - | - | - | - | - | - | - | - |
| Net Debt | $(6,152)$ | $(6,000)$ | $(6,392)$ | $(6,568)$ | $(5,236)$ | $(5,245)$ | - | - | +754 |
| Equity Capital Ratio | 65.5\% | 65.5\% | 64.2\% | 69.2\% | 71.4\% | 73.5\% | - | - | - |
| Net-Debt-Equity Ratio | (50.9\%) | (47.9\%) | (50.4\%) | (49.6\%) | (41.3\%) | (40.8\%) | - | - | - |
| ROE (12 months) | 11.1\% | 12.6\% | 9.0\% | 11.6\% | 12.5\% | 9.5\% | - | - | - |
| ROA (12 months) | 12.3\% | 13.2\% | 9.4\% | 10.4\% | 11.5\% | 8.7\% | - | - | - |
| Total Assets Turnover | 97\% | 111\% | 80\% | 127\% | 109\% | 98\% | - | - | - |
| Inventory Turnover | 3.8 | 4.1 | 2.6 | 5.0 | 4.3 | 4.1 | - | - | - |
| Days of Inventory | 97 | 90 | 139 | 73 | 84 | 90 | - | - | - |
| Quick Ratio | 174\% | 176\% | 159\% | 198\% | 206\% | 223\% | - | - | - |
| Current Ratio | 237\% | 240\% | 230\% | 266\% | 280\% | 301\% | - | - | - |

Cash Flow Statement (Cumulative)

| Cash Flow Statement (Million Yen) | $\begin{array}{r} \text { Cons.Act } \\ \text { Q1 } \\ 02 / 2018 \end{array}$ | Cons.Act Q1 to Q2 02/2018 | Cons.Act Q1 to Q3 02/2018 | $\begin{array}{r} \text { Cons.Act } \\ \text { Q1 to Q4 } \\ 02 / 2018 \end{array}$ | Cons.Act <br> 02/2019 | Cons.Act Q1 to Q2 02/2019 | Cons.Act Q1 to Q3 02/2019 |  | $\begin{array}{r} \text { YoY } \\ \text { Net Chg. } \end{array}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Operating Cash Flow | - | (375) | - | 594 | - | (230) | - | - | +145 |
| Investment Cash Flow | - | (224) | - | (493) | - | (190) | - | - | +34 |
| Operating CF \& Investment CF | - | (600) | - | 100 | - | (420) | - | - | +179 |
| Financing Cash Flow | - | (368) | - | (499) | - | (918) | - | - | (550) |

Source: Company Data, WRJ Calculation

## Disclaimer

Information here is a summary of "IR Information" of the Company, compiled by Walden Research J apan, from a neutral and professional standing point, in the form of a report. "IR Information" of the Company comprises a) contents of our interview with the Company, b) contents of presentations for institutional investors, c) contents of timely disclosed information and d) contents of the homepage etc.

Company name: Walden Research J apan Incorporated
Head office: 4F Hulic Ginza 1-chome Building, 1-13-1 Ginza, Chuo-city, Tokyo 104-0061 J APAN
URL: www.walden.co.jp
E-mail: info@walden.co.jp
Phone : +81 335533769

